Curative Biotechnology Inc (CUBT)

[Gonzal]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421975/

In conclusion, our results demonstrate that IMT504 has an effect not only at the immunological level, as we described previously (Bianchi et al., 2016), but also directly on ß-cells in the diabetic condition. These results are in agreement with our previous results in STZ-induced diabetic rats, in which the immune system does not play a role in diabetes development, and a marked IMT504-induce recovery of ß-cells was observed (Bianchi et al., 2010). Thus, our data support the fact that part of the effects of IMT504 observed in vivo are due to direct effects on ß-cell function, increasing its potential as a therapy for diabetes.